Shareholder Votes

URBAN ONE, INC. shareholders approved Approval of the Urban One, Inc. 2026 Equity and Performance Incentive Plan at the 2026-06-11 meeting.

“Approval of the Urban One, Inc. 2026 Equity and Performance Incentive Plan The results of the voting included 3,083,564 votes for, 41,890 votes against, and 217,508 votes abstained.”

URBAN ONE, INC. shareholders approved Election of directors (Class A and Class B) at the 2026-06-11 meeting.

“Board of Director Election Results Class A Director Nominee Votes For Votes Withheld Non-Votes Terry L. Jones 218,773 45,583 216,776 Brian W. McNeill 218,694 45,662 216,776 Class B Director Nominee Catherine L. Hughes 3,082,577 43,609 216,776 Alfred C. Liggins, III 3,084,113 42,073 216,776 B. Doyle Mitchell, Jr. 3,083,446 42,740 216,776 D. Geoffrey Armstrong 3,081,780 44,406 216,776 The six nominees were elected to the Board of Directors”

OXBRIDGE RE HOLDINGS Ltd shareholders approved Advisory vote on executive compensation at the 2026-06-12 meeting.

“Proposal 3: Approval of the compensation of the Company’s named Executive Officers The proposal to cast a non-binding advisory vote on a resolution approving the compensation of the Company’s named executive officers as disclosed pursuant to the compensation disclosure rules of the Securities and Exchange Commission. was approved as follows: For Against Abstain Broker Non-Votes 2,130,908 586,173 69,902 1,896,269”

OXBRIDGE RE HOLDINGS Ltd shareholders approved Ratification of the Appointment of Independent Auditor at the 2026-06-12 meeting.

“Proposal 2: Ratification of the Appointment of Independent Auditor The appointment of Hacker, Johnson & Smith, P.A. as the Company’s independent auditor for the fiscal year ending December 31, 2026 was ratified as set forth below: For Against Abstain Broker Non-Votes 4,389,427 140,608 153,217 -”

OXBRIDGE RE HOLDINGS Ltd shareholders approved Election of Directors at the 2026-06-12 meeting.

“Proposal 1: Election of Directors Five nominees for the Board of Directors were elected to serve as directors of the Company, each to hold office in accordance with the Articles of Association of the Company until the annual general meeting of shareholders of the Company in 2027. The tabulation of votes was as follows: Director Nominee Votes For Votes Against Abstain Broker Non-Votes Sanjay Madhu 2,593,023 179,956 14,004 1,896,269 Arun Gowda 2,585,419 187,560 14,004 1,896,269 Dwight Merren 2,507,661 265,318 14,004 1,896,269 Wrendon Timothy 2,492,810 280,169 14,004 1,896,269 Lesley Thompson 2,432,035 265,449 89,499 1,896,269”

Black Stone Minerals, L.P. shareholders approved Approval, on a Non-binding Advisory Basis, of the Compensation of the General Partner’s Named Executive Officers at the 2026-06-11 meeting.

“Votes For Votes Against Votes Abstain Broker Non-Vote 73,430,230 2,962,917 1,534,291 56,465,578”

Black Stone Minerals, L.P. shareholders approved Ratification of Appointment of the Partnership’s Independent Registered Public Accounting Firm at the 2026-06-11 meeting.

“Votes For Votes Against Votes Abstain Broker Non-Vote 133,664,053 470,980 257,983 0”

Black Stone Minerals, L.P. shareholders approved Election of Directors at the 2026-06-11 meeting.

“Nominee Votes For Votes Withheld Broker Non-Vote Thomas L. Carter, Jr..................................................... 75,261,407 2,665,427 56,466,393”

Cullinan Therapeutics, Inc. shareholders approved Advisory Vote on Executive Compensation at the 2026-06-16 meeting.

“The Company's stockholders approved the advisory vote on the compensation of the Company's named executive officers by the following votes: Votes For Votes Against Abstentions Broker Non-Votes 48,536,734 1,092,209 7,057 4,126,430”

Cullinan Therapeutics, Inc. shareholders approved Ratification of Appointment of KPMG LLP as Independent Registered Public Accounting Firm at the 2026-06-16 meeting.

“The Company's stockholders ratified the appointment of KPMG LLP as the Company's independent registered accounting firm for the fiscal year ending December 31, 2026 by the following votes: Votes For Votes Against Abstentions Broker Non-Votes 53,722,477 36,815 3,138 0”

Cullinan Therapeutics, Inc. shareholders approved Election of Class III Directors at the 2026-06-16 meeting.

“The Company's stockholders elected two Class III directors to the Company's Board of Directors for three-year terms or until his successor has been duly elected and qualified, or until his earlier death, resignation or removal, by the following votes: Nominee Votes For Votes Withheld Broker Non-Votes Nadim Ahmed 37,519,241 12,116,759 4,126,430 Stephen Webster 36,963,086 12,672,914 4,126,430”

PennyMac Mortgage Investment Trust shareholders approved Approval, by non-binding vote, of the Company's executive compensation at the 2026-06-16 meeting.

“Proposal 3: Approval, by non-binding vote, of the Company’s executive compensation. Votes For Votes Against Abstentions Broker Non-Votes 50,034,544 1,918,452 364,987 18,557,402”

PennyMac Mortgage Investment Trust shareholders approved Ratification of the appointment of Deloitte & Touche LLP as independent registered public accounting firm for the Company for the fiscal year ending December 31, 2026 at the 2026-06-16 meeting.

“Proposal 2: Ratification of the appointment of Deloitte & Touche LLP as independent registered public accounting firm for the Company for the fiscal year ending December 31, 2026. Votes For Votes Against Abstentions Broker Non-Votes 68,988,146 1,607,824 279,415 —”

PennyMac Mortgage Investment Trust shareholders approved Election of three Class II trustee nominees to serve on the Board of Trustees until the 2029 Annual Meeting of Shareholders at the 2026-06-16 meeting.

“Proposal 1: The election of three (3) Class II trustee nominees to serve on the Board of Trustees until the 2029 Annual Meeting of Shareholders. Trustee Votes For Votes Against Abstentions Broker Non-Votes Preston DuFauchard 40,416,570 11,760,494 140,919 18,557,402 Nancy McAllister 49,835,723 2,352,649 129,611 18,557,402 Stacey D. Stewart 37,190,340 14,990,183 137,460 18,557,402”

Silence Therapeutics plc shareholders approved To approve the application of Article 159 of the Company's articles of association from the conclusion of this AGM to the conclusion of the next annual general meeting of the Company. at the 2026-06-16 meeting.

“Resolution 9 : To approve the application of Article 159 of the Company's articles of association from the conclusion of this AGM to the conclusion of the next annual general meeting of the Company. The votes were cast as follows: For Against Abstain 48,307,317 9,333 4,405,761”

Silence Therapeutics plc shareholders approved To approve the directors' remuneration report for the year ended December 31, 2025, which is set forth as Annex A to the Proxy Statement and on pages 32 to 54 (inclusive) of the 2025 U.K. Annual Report. at the 2026-06-16 meeting.

“Resolution 8 : To approve the directors' remuneration report for the year ended December 31, 2025, which is set forth as Annex A to the Proxy Statement and on pages 32 to 54 (inclusive) of the 2025 U.K. Annual Report. The votes were cast as follows: For Against Abstain 48,251,875 66,518 4,404,018”

Silence Therapeutics plc shareholders approved To receive and adopt the Company's U.K. statutory annual accounts and reports for the year ended December 31, 2025 (the “2025 U.K. Annual Report”). at the 2026-06-16 meeting.

“Resolution 7 : To receive and adopt the Company's U.K. statutory annual accounts and reports for the year ended December 31, 2025 (the “2025 U.K. Annual Report”). The votes were cast as follows: For Against Abstain 52,715,076 3,108 4,077”

Silence Therapeutics plc shareholders approved To authorize the Audit & Risk Committee to determine the U.K. statutory auditors' remuneration for the year ending December 31, 2026. at the 2026-06-16 meeting.

“Resolution 6 : To authorize the Audit & Risk Committee to determine the U.K. statutory auditors' remuneration for the year ending December 31, 2026. The votes were cast as follows: For Against Abstain 52,714,237 6,155 1,869”

Silence Therapeutics plc shareholders approved To re-appoint PricewaterhouseCoopers LLP as the Company's U.K. statutory auditors, to hold office until the conclusion of the next annual general meeting of shareholders. at the 2026-06-16 meeting.

“Resolution 5 : To re-appoint PricewaterhouseCoopers LLP as the Company's U.K. statutory auditors, to hold office until the conclusion of the next annual general meeting of shareholders. The votes were cast as follows: For Against Abstain 52,718,407 2,885 1,119”

Silence Therapeutics plc shareholders approved To ratify the appointment of PricewaterhouseCoopers LLP as the Company's U.S. independent registered public accounting firm for the year ending December 31, 2026. at the 2026-06-16 meeting.

“Resolution 4 : To ratify the appointment of PricewaterhouseCoopers LLP as the Company's U.S. independent registered public accounting firm for the year ending December 31, 2026. The votes were cast as follows: For Against Abstain 52,718,407 2,885 1,119”

Silence Therapeutics plc shareholders approved To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement. at the 2026-06-16 meeting.

“Resolution 3 : To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement. The votes were cast as follows: For Against Abstain 48,234,208 73,667 4,414,536”

Silence Therapeutics plc shareholders approved To re-appoint as a director of the Company James Ede-Golightly. at the 2026-06-16 meeting.

“Resolution 2 : To re-appoint as a director of the Company James Ede-Golightly. The votes were cast as follows: For Against Abstain 52,112,045 605,683 4,680”

Silence Therapeutics plc shareholders approved To re-appoint as a director of the Company Rhonda Hellums. at the 2026-06-16 meeting.

“Resolution 1 : To re-appoint as a director of the Company Rhonda Hellums. The votes were cast as follows: For Against Abstain 47,160,731 5,557,090 4,680”

ELUTIA INC. shareholders approved Approval, on an advisory, non-binding basis, of the frequency of future advisory say-on-pay votes at the 2026-06-11 meeting.

“Proposal 5 – Approval, on an advisory, non-binding basis, of the frequency of future advisory say-on-pay votes: ​ ​ Every 1 Year Every 2 Years Every 3 Years Abstain Broker Non-Votes 20,932,402 1,849,469 4,161,721 149,728 6,948,225 ​ Accordingly, the Company’s stockholders recommended a frequency of “Every 1 Year” for Proposal 5 set forth above.”

ELUTIA INC. shareholders approved Approval, on an advisory, non-binding basis of the compensation of the Company’s named executive officers at the 2026-06-11 meeting.

“Proposal 4 – Approval, on an advisory, non-binding basis of the compensation of the Company’s named executive officers: ​ ​ ​ ​ ​ ​ ​ ​ Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 25,617,864 336,249 1,139,206 6,948,226 ​ Accordingly, the Company’s stockholders approved Proposal 4 set forth above.”

ELUTIA INC. shareholders approved Approval of the First Amendment to the Elutia Inc. Amended and Restated 2020 Incentive Award Plan at the 2026-06-11 meeting.

“Proposal 3 – Approval of the First Amendment to the Elutia Inc. Amended and Restated 2020 Incentive Award Plan: ​ ​ ​ ​ ​ ​ ​ ​ Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 22,421,769 3,540,699 1,130,851 6,948,226 ​ Accordingly, the Company’s stockholders approved Proposal 3 set forth above.”

ELUTIA INC. shareholders approved Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026 at the 2026-06-11 meeting.

“Proposal 2 – Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026: ​ ​ ​ ​ ​ ​ ​ Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 33,866,728 174,255 562 - ​ Accordingly, the Company’s stockholders approved Proposal 2 set forth above.”

ELUTIA INC. shareholders approved Election of two Class III directors to hold office until the Company’s annual meeting of stockholders to be held in 2029 and until their respective successors have been duly elected and qualified at the 2026-06-11 meeting.

“Proposal 1 – Election of two Class III directors to hold office until the Company’s annual meeting of stockholders to be held in 2029 and until their respective successors have been duly elected and qualified: ​ ​ ​ ​ ​ Votes FOR Votes WITHHELD Broker Non-Votes David Colpman 25,384,500 1,708,821 6,948,224 Kevin Rakin 26,902,953 190,368 6,948,224 ​ Accordingly, the nominees for Class III directors were elected.”

BillionToOne, Inc. shareholders approved Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-10 meeting.

“Proposal 2: The ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026: For Against Abstentions 77,277,103 197 20,844 As a routine proposal under applicable rules, no broker non-votes were recorded in connection with this proposal.”

BillionToOne, Inc. shareholders approved The election of two directors to serve as Class I directors until the 2029 annual meeting of stockholders and until their respective successors are duly elected and qualified at the 2026-06-10 meeting.

“Proposal 1: The election of two directors to serve as Class I directors until the 2029 annual meeting of stockholders and until their respective successors are duly elected and qualified: Name For Withheld Broker Non-Votes Oguzhan Atay 76,387,783 348,276 562,085 Akshay Rai 76,297,791 438,268 562,085”

Centurion Acquisition Corp. shareholders approved Proposal to amend the Company's Amended and Restated Memorandum and Articles of Association to extend the date by which the Company must consummate a business combination from June 12, 2026 to June 12, 2027 at the 2026-06-12 meeting.

“On June 12, 2026, Centurion Acquisition Corp. (the “Company”) held an extraordinary general meeting of shareholders (the “Extraordinary General Meeting”) at which its shareholders approved a proposal to amend the Company’s Amended and Restated Memorandum and Articles of Association (the “Articles”) to extend the date by which the Company must consummate a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar initial business combination from June 12, 2026 to June 12, 2027 (the “Extended Date”), or an earlier date than the Extended Date as determined by the Company’s board of directors and included in a public announcement (the “Extension Amendment”).”

Matador Resources Co shareholders approved Proposal to Ratify the Appointment of KPMG LLP as the Company’s Independent Registered Public Accounting Firm for the Year Ending December 31, 2026 at the 2026-06-11 meeting.

“Proposal 3: Proposal to Ratify the Appointment of KPMG LLP as the Company’s Independent Registered Public Accounting Firm for the Year Ending December 31, 2026 The shareholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026. Votes For Votes Against Votes Abstained 114,318,225 1,164,026 257,553”

Matador Resources Co shareholders approved Advisory Vote on 2025 Executive Compensation at the 2026-06-11 meeting.

“Proposal 2: Advisory Vote on 2025 Executive Compensation The shareholders approved the non-binding advisory resolution approving the 2025 compensation of the Company’s named executive officers. Votes For Votes Against Votes Abstained Broker Non-Votes 105,024,470 4,302,089 332,051 6,081,194”

Matador Resources Co shareholders approved Election of Directors at the 2026-06-11 meeting.

“Proposal 1: Election of Directors The shareholders elected each of Joseph Wm. Foran, Reynald A. Baribault and Timothy E. Parker as a Class III director of the Company for a term expiring at the Annual Meeting of Shareholders in 2029. Each such director shall serve for the applicable term or the earlier death, retirement, resignation or removal of such director. Nominee Votes For Votes Against Votes Abstained Broker Non-Votes Joseph Wm. Foran 108,404,472 1,050,044 204,094 6,081,194 Reynald A. Baribault 95,218,912 14,206,253 233,445 6,081,194 Timothy E. Parker 100,184,684 9,240,261 233,665 6,081,194”

BATTALION OIL CORP shareholders approved Ratification of appointment of Deloitte & Touche LLP as independent registered public accounting firm at the 2026-06-11 meeting.

“The second proposal was the ratification of the appointment of Deloitte & Touche LLP, an independent registered public accounting firm, as the Company’s independent registered public accountants for the fiscal year ending December 31, 2026. The ratification of the appointment of Deloitte & Touche LLP was approved as follows: Proposal 2 — Ratification of Independent Auditor Votes For Votes Against Abstentions Ratification of Deloitte & Touche LLP 11,424,647 96,903 30,821”

BATTALION OIL CORP shareholders approved Election of four directors at the 2026-06-11 meeting.

“On June 11, 2026, Battalion Oil Corporation (the “ Company ”) convened its 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting ”), at which the Company’s stockholders voted on two proposals. The first proposal was to elect four nominees to serve as directors of the Company until the next annual meeting of stockholders, and until their successors are elected and qualified or until their earlier resignation, removal from office, death or incapacity. Each of the four nominees for directors were elected as follows: Proposal 1 — Election of Directors Nominees for Directors Votes For Withheld Jonathan D. Barrett 6,807,092 ​ 115,360 ​ Gregory S. Hinds 6,809,797 ​ 112,655 ​ William D. Rogers 6,802,871 ​ 119,581 ​ Matthew B. Steele ​ 6,806,617 ​ 115,835”

Ingersoll Rand Inc. shareholders approved Approval of Ingersoll Rand Inc. 2026 Omnibus Incentive Plan at the 2026-06-11 meeting.

“The Company’s stockholders approved the 2026 Plan.”

Ingersoll Rand Inc. shareholders approved Non-Binding Vote to Approve Executive Compensation at the 2026-06-11 meeting.

“The Company’s stockholders approved, on an advisory (non-binding) basis, the compensation of the Company’s named executive officers as described in the Proxy Statement.”

Ingersoll Rand Inc. shareholders approved Ratification of Independent Registered Public Accounting Firm at the 2026-06-11 meeting.

“The Company’s stockholders ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for fiscal 2026.”

Ingersoll Rand Inc. shareholders approved Election of Directors at the 2026-06-11 meeting.

“The Company’s stockholders elected the persons listed below as directors for a term expiring at the Company’s 2027 annual meeting of stockholders or until their respective successors are duly elected and qualified.”

Datadog, Inc. shareholders rejected Adoption of a Simple Majority Voting Provision at the 2026-06-15 meeting.

“Proposal 4 – Adoption of a Simple Majority Voting Provision Stockholders did not approve a shareholder proposal regarding the adoption of a simple majority voting provision, by the following votes: Votes For Votes Against Votes Abstain Broker Non-Votes 217,163,770 296,078,084 489,664 27,229,324”

Datadog, Inc. shareholders approved Ratification of the Selection of Independent Registered Public Accounting Firm at the 2026-06-15 meeting.

“Proposal 3 – Ratification of the Selection of Independent Registered Public Accounting Firm Stockholders ratified the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026, by the following votes: Votes For Votes Against Votes Abstain 539,501,723 1,223,828 235,291”

Datadog, Inc. shareholders approved Approval, on a Non-Binding, Advisory Basis, of the Compensation of the Company’s Named Executive Officers at the 2026-06-15 meeting.

“Proposal 2 – Approval, on a Non-Binding, Advisory Basis, of the Compensation of the Company’s Named Executive Officers Stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement, by the following votes: Votes For Votes Against Votes Abstain Broker Non-Votes 492,631,049 20,881,163 219,306 27,229,324”

Datadog, Inc. shareholders approved Election of Directors at the 2026-06-15 meeting.

“Proposal 1 – Election of Directors Olivier Pomel, Dev Ittycheria, Shardul Shah and Ami Vora were each elected to serve as a Class I director of the Company’s Board of Directors until the 2029 Annual Meeting of Stockholders and until their successor is duly elected and qualified or until their earlier resignation or removal, by the following votes: Nominee Votes For Votes Withheld Broker Non-Votes Olivier Pomel 503,784,971 9,946,547 27,229,324 Dev Ittycheria 455,983,503 57,748,015 27,229,324 Shardul Shah 430,291,897 83,439,621 27,229,324 Ami Vora 512,745,718 985,800 27,229,324”

Armata Pharmaceuticals, Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026. at the 2026-06-11 meeting.

“Also at the Meeting, our shareholders ratified the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. The vote for such ratification was 29,842,514 shares for, 6,631 shares against, 558 shares abstaining, and 0 shares of broker non-votes.”

Armata Pharmaceuticals, Inc. shareholders approved Approval, on a non-binding advisory basis, of a one-year frequency for future advisory votes on named executive officer compensation. at the 2026-06-11 meeting.

“At the Meeting, our shareholders next approved, on a non-binding advisory basis, a one-year frequency for future advisory votes on the Company’s named executive officer compensation. The vote for such approval was 28,567,809 shares for one year, 2,400 shares for two years, 17,113 shares for three years, 4,914 shares abstaining, and 1,257,467 shares of broker non-votes.”

Armata Pharmaceuticals, Inc. shareholders approved Approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers. at the 2026-06-11 meeting.

“At the Meeting, our shareholders next approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers. The vote for such approval was 28,547,283 shares for, 27,765 shares against, 17,188 shares abstaining, and 1,257,467 shares of broker non-votes.”

Armata Pharmaceuticals, Inc. shareholders approved Election of seven directors to serve for a one-year term at the 2026-06-11 meeting.

“At the Annual Meeting of Shareholders held on June 11, 2026 (the “Meeting”), the shareholders of Armata Pharmaceuticals, Inc. (the “Company”) elected seven members to our board of directors, each for a one-year term expiring at the annual meeting of shareholders in 2027, as follows: Members Number of Shares Voted For Number of Shares Withheld Broker Non- Votes Deborah L. Birx, M.D. 28,349,266 242,970 1,257,467 Daniel B. Gilmer, Ph.D. 28,543,542 48,694 1,257,467 Jules Haimovitz 28,350,690 241,546 1,257,467 Odysseas D. Kostas, M.D. 28,353,918 238,318 1,257,467 Robin C. Kramer 28,537,772 54,464 1,257,467 Joseph M. Patti, Ph.D. 28,544,094 48,142 1,257,467 Sarah Schlesinger, M.D. 28,354,046 238,190 1,257,467”

NASDAQ, INC. shareholders approved Ratification of the Appointment of Ernst & Young LLP as Nasdaq’s Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2026 at the 2026-06-10 meeting.

“FOR AGAINST ABSTAIN BROKER NON-VOTES Proposal 3: Ratification of the Appointment of Ernst & Young LLP as Nasdaq’s Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2026 376,643,806 22,134,699 166,909 0”

NASDAQ, INC. shareholders approved Approval of the Company’s Executive Compensation on an Advisory Basis at the 2026-06-10 meeting.

“FOR AGAINST ABSTAIN BROKER NON-VOTES Proposal 2: Approval of the Company’s Executive Compensation on an Advisory Basis 357,897,727 13,506,434 1,253,128 26,189,922”